Abstract

The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma.

Knowledge from population studies of the long-term risk of chronic HBV infection, as well as the recent introduction of pegylated interferon and additional nucleoside analogues has changed the therapeutic situation.

Recently, a Swedish expert panel convened to update the national recommendations for treatment.

The panel recommends treatment for patients with active HBV infection causing protracted liver inflammation or significant liver ...

Esta siendo redirigido al contenido completo...